Cargando…

Off‐target ACE2 ligands: Possible therapeutic option for CoVid‐19?

Detalles Bibliográficos
Autores principales:	Brogi, Simone, Calderone, Vincenzo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7256127/ https://www.ncbi.nlm.nih.gov/pubmed/32359080 http://dx.doi.org/10.1111/bcp.14343

Ejemplares similares

Telemedicine against CoVID-19 crisis
por: Ajami, Sima, et al.
Publicado: (2020)

Changes in burn referrals and injuries during CoVid-19
por: Chu, H., et al.
Publicado: (2020)

Selective Estrogen Receptor Modulators in COVID-19: A Possible Therapeutic Option?
por: Calderone, Alba, et al.
Publicado: (2020)

Colchicine as a possible therapeutic option in COVID-19 infection
por: Parra-Medina, Rafael, et al.
Publicado: (2020)

GCP III is not the “off-target” for urea-based PSMA ligands
por: Lee, Zhenghong, et al.
Publicado: (2023)

Low risk for SARS-CoV2 symptomatic infection and early complications in paediatric patients during the ongoing CoVID19 epidemics in Lombardy
por: Rovida, F., et al.
Publicado: (2020)

Targeting Opioid Receptors in Addiction and Drug Withdrawal: Where Are We Going?
por: Tabanelli, Rita, et al.
Publicado: (2023)

From the Ketogenic Diet to the Mediterranean Diet: The Potential Dietary Therapy in Patients with Obesity after CoVID-19 Infection (Post CoVID Syndrome)
por: Barrea, Luigi, et al.
Publicado: (2022)

An epidemiological study exploring a possible impact of treatment with ACE inhibitors or angiotensin receptor blockers on ACE2 plasma concentrations
por: Wild, Philipp S., et al.
Publicado: (2020)

CoVid-19 related dactyitis
por: Salvatierra, Juan, et al.
Publicado: (2020)

Nanobiotechnology in combating CoVid-19
por: Ganapathy, Dhanraj, et al.
Publicado: (2020)

Pharmacologic therapeutic options for thromboprophylaxis in COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2020)

Pulmonary lipid modulation: A possible therapeutic target for SARS-CoV-2 infection
por: Mandato, Claudia, et al.
Publicado: (2021)

ACE2, a drug target for COVID-19 treatment?
por: Liu, Yang, et al.
Publicado: (2022)

COVID-19 therapeutic options for patients with kidney disease
por: Izzedine, Hassan, et al.
Publicado: (2020)

Molecular docking analysis of quercetin with known CoVid-19 targets
por: Chandran, Sridevi Chandra Subash, et al.
Publicado: (2023)

Role of hydrogen sulfide in endothelial dysfunction: Pathophysiology and therapeutic approaches
por: Citi, Valentina, et al.
Publicado: (2020)

Is Sildenafil a Therapeutic Option for Noncompaction?
por: Finsterer, Josef, et al.
Publicado: (2014)

Nutritional recommendations for CoVID-19 quarantine
por: Muscogiuri, Giovanna, et al.
Publicado: (2020)

Éthique, déontologie et CoVid-19
por: Julien, Henri
Publicado: (2022)

Improving Curcumin Bioavailability: Current Strategies and Future Perspectives
por: Tabanelli, Rita, et al.
Publicado: (2021)

Clofazimine: A potential therapeutic option for severe COVID-19
por: Ateya, Areej Mohamed
Publicado: (2021)

Mycophenolate mofetil as a possible therapeutic option for idiopathic membranoproliferative glomerulonephritis
por: Kazory, Amir, et al.
Publicado: (2008)

High Expression of ACE2 on Keratinocytes Reveals Skin as a Potential Target for SARS-CoV-2
por: Xue, Xiaotong, et al.
Publicado: (2021)

Steroids: A Therapeutic Option for COVID-19 Pneumonia Patients With ESRD?
por: Delafosse, Marion, et al.
Publicado: (2020)

Possible Neurological and Mental Outcomes of COVID-19 Infection: A Hypothetical Role of ACE-2\Mas\BDNF Signaling Pathway
por: Motaghinejad, Majid, et al.
Publicado: (2020)

Dead in the air- The need to adapt to CoVID adaptations
por: Kuehnel, Nicholas A., et al.
Publicado: (2021)

Comments on nutritional recommendations for CoVID-19 quarantine
por: Herrera-Peco, Iván, et al.
Publicado: (2021)

Data on steam inhalation in combating CoVid-19
por: Kumar, Barun Dev, et al.
Publicado: (2022)

The Role of Radiotherapy Among the Therapeutic Options for Castleman’s Disease
por: Karaca, Feryal, et al.
Publicado: (2014)

Bromelain inhibits SARS‐CoV‐2 infection via targeting ACE‐2, TMPRSS2, and spike protein
por: Sagar, Satish, et al.
Publicado: (2021)

ACE polymorphism and COVID-19 outcome
por: Delanghe, Joris R., et al.
Publicado: (2020)

Inhibition of endocytic recycling of ACE2 by SARS-CoV-2 S protein partially explains multiple COVID-19 related diseases caused by ACE2 reduction
por: Ren, Yongwen, et al.
Publicado: (2022)

Enhanced trimeric ACE2 exhibits potent prophylactic and therapeutic efficacy against the SARS-CoV-2 Delta and Omicron variants in vivo
por: Li, Mengjiao, et al.
Publicado: (2022)

Disruption of Irisin Dimerization by FDA-Approved Drugs: A Computational Repurposing Approach for the Potential Treatment of Lipodystrophy Syndromes
por: Flori, Lorenzo, et al.
Publicado: (2023)

The looming pandemic of COVID-19: What therapeutic options do we have now?
por: Afsar, Nasir Ali
Publicado: (2020)

“COVID-19 associated divergent thrombotic thrombocytopenic purpura (TTP) syndromes reported so far, five and counting”: Classification and possible therapeutic options
por: Mir, Tajamul H.
Publicado: (2022)

SARS-CoV-2 ACE-receptor detection in the placenta throughout pregnancy
por: Gengler, Carole, et al.
Publicado: (2021)

Sars-CoV-2 and black population: ACE2 as shield or blade?
por: Vinciguerra, Mattia, et al.
Publicado: (2020)

ACE-inhibitor/angiotensin receptor blockers (ACE-I/ARBs) therapy in COVID-19 infected dialysis patients
por: Daoud, Ahmed, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_u60s9lnu2s0iscld4c6lunvgcq